Author | D. Ross Camidge, MD, PhD | OncLive

Author | D. Ross Camidge, MD, PhD

Articles

Dr. Camidge Discusses Treatment of Patients With ALK+ NSCLC

January 24, 2019

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment strategies for patients with ALK-mutated non–small cell lung cancer.

Dr. Camidge on Mechanisms of Resistance to TKIs in NSCLC

November 27, 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to targeted therapies in oncogene-driven non–small cell lung cancer.

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

November 10, 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLC

October 31, 2018

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.

x